Vulvar and Vaginal Atrophy (VVA) Therapy Market Size & Share, by Symptoms (Vaginal Dryness, Burning Sensation in the Vagina, Dyspareunia, Urinary Tract Infection); Diagnosis (Pelvic Examination, Urine Test, Acid Balance Test); Treatment (Non-Hormonal Therapy, Hormonal Therapy, Laser Therapy); End-user (Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4178
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Vulvar And Vaginal Atrophy (Vva) Therapy Market size is expected to reach USD 5 Billion by the end of 2035, growing at a CAGR of 11% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of vulvar and vaginal atrophy (VVA) therapy USD 2 Billion. The growth of the market can be attributed to the rising number of cases related to the hypoestrogenism condition, known as genitourinary syndrome of menopause (also known as vulvovaginal atrophy or urogenital trophy), among women. For instance, the menopausal genitourinary syndrome affects approximately 30% to 75% of postmenopausal women and can significantly impair health, sexual function, and quality of life.  

Global vulvar and vaginal atrophy (VVA) therapy market trends such as rising awareness about VVA therapies among the female population, the vulvar and vaginal atrophy therapy market size is expected to expand notably during the forecast year.  According to the National Institute of Health, approximately 1.3 million women in the United States enter menopause each year. The age of menopause begins mostly between 51 and 52 years of age.  However, approximately 5% of women worldwide experience early menopause between the ages of 40 and 45, and 1% experience premature menopause, i.e., before the age of 40, due to sex chromosomal abnormalities, resulting in permanent ovarian failure. Hence, all these factors are expected to hike the market growth over the forecast period.


Vulvar-and-Vaginal-Atrophy-(VVA)-Therapy-market-scope
Get more information on this report: Request Free Sample PDF

Vulvar And Vaginal Atrophy (Vva) Therapy Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Female Geriatric Population - According to the United Nations Department of Economic and Social Affairs, World Population Ageing 2020 Highlights report, there is a rapid growth of the aging population. An estimated 727 million people are aged 65 or more in 2020. The number is forecasted to reach over 1.5 billion people, almost more than double from 9.3% in 2020 to 16% in 2050. According to the data, on average, women live longer than men. The total aging population comprises 55% of the female population aged 65 years and above.

  • Increasing Incidences of Breast Cancer and Uterine Cancer in Women - Breast cancer has been found to affect the body’s hormones. In women, about 67%-80% of breast cancer cases are estrogen receptor (ER) positive, while in men, around 90% and 80% are estrogen receptor (ER) and progesterone receptor (PR) positive, respectively. According to the World Health Organization (WHO), in 2020, 2.3 million women were diagnosed with breast cancer worldwide. On the other hand, according to the National Cancer Institute, as of 2022, uterine cancer represents 3.4% of all new cancer cases in the United States.

  • Growing Healthcare Expenditure - According to the Centers for Medicare & Medicaid Services, national health spending in the United States is expected to grow at a 5.5 percent annual rate, reaching approximately USD 6.0 trillion by the end of 2027.

  • Increasing Lifestyle-Related Diseases in Women- Lifestyle diseases, associated with physical inactivity and poor diet quality, pose a significant health burden. Gestational diabetes mellitus (GDM), type 2 diabetes (DM2), and polycystic ovary syndrome (PCOS) are a few of the lifestyle-related diseases that affect women. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (up to 5 million) of US women of reproductive age as of 2020. Certain lifestyle disorders, such as depression, insomnia, and weight gain, are also common among women.

  • Growing Prevalence of UTI – The prevalence of UTI is very higher and a considerable number of women across the globe aren’t aware of it. It is estimated that, in every 25 women, 10 of them suffer from urinary tract infections.

Challenges

  • Unreported Cases of Genitourinary Syndrome of Menopause Owing to a Lack of Awareness - A significant number of women aren’t aware of this therapy. In the rural areas of most developing countries, women have no awareness of even UTI, and the burning sensation is very high. Women give no particular attention to these diseases since many of them hesitate to elaborate on the symptoms. Hence, such hesitance and lack of awareness are estimated to limit the market growth over the forecast period.
  • Concerns about Vulvar and Vaginal Atrophy from Cancer Combination Treatments
  • Adverse Effect on the Quality of Life

Vulvar And Vaginal Atrophy (Vva) Therapy Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~11%

Base Year Market Size (2022)

~ USD 2 Billion

Forecast Year Market Size (2035)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Vulvar And Vaginal Atrophy (Vva) Therapy Segmentation

Treatment (Non-Hormonal Therapy, Hormonal Therapy, Laser Therapy)

The global vulvar and vaginal atrophy (VVA) therapy market is segmented and analyzed for demand and supply by treatment into non-hormonal therapy, hormonal therapy, and laser therapy. Out of these types of treatment, the hormonal therapy segment is estimated to gain the largest market share in the year 2035. The growth of the segment can be attributed to the growing number of vaginal cancer cases as the therapy lessens the chances of cancer recurrence. For instance, according to the Centers for Disease Control and Prevention, in 2019, around 1,368 women were diagnosed with vaginal cancer in the United States. On the other hand, most women have menopausal hormone therapy (MHT) also known as hormone replacement therapy (HRT) if they experience symptoms associated with menopause. Additionally, hormonal therapy is also used to treat breast cancer using hormones to grow. Hence, such a higher utilization is anticipated to spike the segment growth over the forecast period.

Diagnosis (Pelvic Examination, Urine Test, Acid Balance Test)

The global vulvar and vaginal atrophy (VVA) therapy market is also segmented and analyzed for demand and supply by diagnosis into pelvic examination, urine test, and acid balance test. Amongst these three segments, the urine test segment is expected to garner a significant share in the year 2035. Urine test is done since they can diagnose almost every type of disorder including UTI, Diabetes, kidney diseases, vaginal cancer, and others. To check for UTI, urine is examined via a microscope to look for bacteria or white blood cells, major signs of infection.

Our in-depth analysis of the global market includes the following segments:

             By Symptoms

  • Vaginal Dryness
  • Dyspareunia
  • Urinary Tract Infection
  • Others

             By Diagnosis

  • Pelvic Examination
  • Urine Test
  • Acid Balance Test

             By Treatment

  • Non-Hormonal Therapy
  • Hormonal Therapy
  • Laser Therapy

            By End-User

  • Hospitals
  • Clinics
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Vulvar And Vaginal Atrophy (Vva) Therapy Industry - Regional Synopsis

North American Market Forecast   

The North American vulvar and vaginal atrophy (VVA) therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the surge in the number of women suffering from pre and postmenopausal hormonal imbalances along with the growing number of vaginal cancer cases in the region. For instance, according to the Centers for Disease Control and Prevention, in 2019, around 5,579 women (2.6 per 100,000) were diagnosed with vulvar cancer in the United States. Additionally, the boom in the instance of urinary tract infection cases in women owing to hypersexuality and unhealthy lifestyle and growing awareness of the infection is further anticipated to expand the regional market size during the forecast period. For instance, in 2022, it was estimated that around 45% of the women living in the USA are prone to get UTIs. Meanwhile, the doctor visits owing to UTIs are observed to be approximately 8 million every year.

APAC Market Statistics

The Asia Pacific vulvar and vaginal atrophy (VVA) therapy market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the growing awareness of vulvar and vaginal atrophy basked by the escalating provision of required medication and the boom in the number of female geriatrics in the region. For instance, it was projected that in 2020, there were nearly 50% of geriatric females in the Asia Pacific. Women above 60 or 65 are considered to be geriatrics and highly prone to vaginal infection on account of the lack of estrogen. On the other hand, the increasing prevalence of UTI and vaginal cancers has also led to a higher demand for VVA therapy which results in a major growth driver to boost the market growth over the forecast period.

Research Nester
Vulvar-and-Vaginal-Atrophy-(VVA)-Therapy-Market-regional
Get more information on this report: Request Free Sample PDF

Companies Dominating the Vulvar And Vaginal Atrophy (Vva) Therapy Landscape

top-features-companies
    • Daré Bioscience, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Almirall, S.A.
    • Viveve, Inc.
    • Lutronic Corporation
    • Venus Concept
    • ThermiGen, LLC
    • Alma Lasers LTD.
    • BTL
    • Fotona d.o.o.
    • TherapeuticsMD, Inc.

In the News

  • Dare Bioscience, Inc. has announced the initiation of the DARE-VVA1’s Phase I/II trial to evaluate a proprietary investigational formulation for the non-hormonal treatment of moderate to severe vulvar and vaginal atrophy (VVA). DARE-VVA1 is a new intravaginal tamoxifen product developed to treat vulvar and vaginal atrophy.

  • TherapeuticsMD, Inc. announced the approval by the U.S. Food and Drug Administration for Imvexxy 4 mcg dose. Imvexxy 4 mcg is now a commercially available drug in the United States for the treatment of dyspareunia, which is a symptom of vulvar and vaginal atrophy.

Author Credits:  Radhika Pawar


  • Report ID: 4178
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of breast cancer and uterine cancer in women and the growing prevalence of UTI are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2023-2035.

Concerns about vulvar and vaginal atrophy from cancer combination treatments are estimated to be the growth-hindering factors for market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Almirall, S.A., Viveve, Inc., Lutronic Corporation, Venus Concept, ThermiGen, LLC, Alma Lasers LTD., BTL, Fotona d.o.o., TherapeuticsMD, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by symptoms, diagnosis, treatment, end-user, and by region.

The hormonal therapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Vulvar and Vaginal Atrophy Therapy Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying